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The presence of concomitant chronic total occlusion in patients with
ischemic heart failure is related with worse long-term outcomes – report
from COMMIT-HF registry.
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BACKGROUND Many reports showed that the presence of concomi-
tant chronic total occlusion (CTO) in a non-culprit lesion in acute
coronary syndromes is associated with impaired prognosis. However,
there is insufﬁcient data evaluating the effect of concomitant CTO in
patients with ischemic systolic heart failure (HF). The aim of our
analysis was to assess the effect of the concomitant CTO on long-term
prognosis in patients with ischemic systolic HF.
METHODS The COMMIT-HF is an ongoing single-center systolic HF
registry (inclusion criteria: HF with LVEF <35%, exclusion: ACS). A
total of 1798 patients were enrolled since 2009. Among them we have
selected a subset of ischemic HF subjects who underwent elective
coronary angiography (n¼675). The patients were divided into two
groups with regard to CTO presence (not protected by a patent
vascular graft). All of the analyzed patients are followed up for a
period of at least 12 months with all-cause mortality deﬁned as pri-
mary endpoint.
RESULTS Baseline patient characteristics are presented in Table 1.
The comparison of echocardiographic parameters and administered
medical treatment showed no signiﬁcant differences. In both groups
around half of subjects had PCI performed (46,7% vs. 56,4%,
p¼0,01). 12-month follow-up revealed signiﬁcantly higher mortality
in the CTO group (19,4% vs 10,3%, p<0,001), evident also after 24
months (26,6% vs. 17,6%, p¼0,01). This was also observed in the
subgroup of pts who underwent PCI (12-month mortality 17,6% vs
9.8%, p¼0,03, 24-month 25,2% vs 18,1%), p¼0,15). Multivariate
analysis revealed that the presence of concomitant CTO was an
independent factor increasing mortality (OR 2,34, 95% CI 1,38-3,96,
p¼0,001).CTO, n[278 Non-CTO, n[397 pSex 236M vs 42F 315M vs 82F 0.06Age 65.410,5 63.910,6 0.07
Mean EF [%] 26.85,5 27.15,9 0.58
Atrial ﬁbrillation [%] 27.7 26.2 0.66NYHA III & IV [%] 44.2 44.3 0.99Chronic kidney disease
stage III-V [%]32.0 30.2 0.68Diabetes [%] 50.0 43.0 0.07Post-CABG [%] 38.0 25.9 0.003Post-MI [%] 76.9 66.2 0.002ICD/CRT-D [%] 64.7 61.4 0.38CONCLUSIONS Our analysis showed that in patients with ischemic
heart failure the presence of the chronic total occlusion is related to
worse long-term outcomes. Therefore, HF patients with concomitant
CTO should always be assessed with regard to the viability of CTO
recanalization.
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BACKGROUND There is limited data on hemodynamic predictors of
renal function in patients with left ventricular diastolic dysfunction
and pulmonary hypertension. Our objective was to analyze the
strength of correlation between standard and novel hemodynamic
indices, including right atrial to pulmonary capillary wedge ratio
(RA:PCWP) and pulmonary artery pulsatility index (PAPi), with renalfunction in patients with diastolic dysfunction {left ventricular ejec-
tion fraction (LVEF) 50%} who had pulmonary hypertension (mean
pulmonary artery pressure >25 mm Hg).
METHODS We retrospectively screened 172 patients with pulmonary
hypertension who underwent a right heart catheterization (RHC) be-
tween 2007 and 2012 at Einstein Medical Center, Philadelphia. A
multivariate logistical regression including standard RHC variables,
pulmonary artery pulse pressure (PAPP), PAPi (PAPP/RA) and
RA:PCWP ratio was used to identify predictors of renal dysfunction
and mortality. Linear regression was used to evaluate PAPi as signif-
icant predictors of length of stay.
RESULTS The ﬁnal cohort consisted of 46 patients, with mean age
60.412.2 years and 78.3% male. Among the standard and novel he-
modynamic indices, only PAPi independently predicted 90-day mor-
tality (OR 0.832, 95% CI 0.703 – 0.985). Patients who died within 90
days (n¼10, 21.7%) had an average lower PAPi than those who sur-
vived (1.930.42 vs 3.560.40, p ¼ 0.05). Patients with PAPi greater
than 2.75 had lower rates of renal dysfunction (deﬁned as worsening
of GFR by greater than 10 mL/min/1.73 m2) at the time of RHC (9.5% vs
28%). Finally, linear regression conﬁrmed that PAPi is negatively
correlated with length of stay (p ¼ 0.013).Variable b P-value OR 95% CIRA 0.51 0.08 1.6 0.92 - 2.9Mean PA -0.01 0.9 0.99 0.85 - 1.15PAPP -0.71 0.21 0.48 0.15 - 1.5PCWP -0.39 0.13 0.67 0.39 - 1.13RA:PCWP -3.4 0.41 0.03 0.1 - 118.4PAPi -0.19 0.03 0.91 0.7 - 0.9Cardiac output 0.31 0.19 1.37 0.85 – 2.2CONCLUSIONS PAPi is a better predictor of length of stay, renal
dysfunction and 90-day mortality than the standard RHC variables in
patients with pulmonary hypertension with preserved ejection
fraction.
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BACKGROUND Despite widespread use of percutaneous coronary
revascularization techniques and short door to balloon times,
myocardial scarring following an acute infarction remains prevalent.
J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y , V O L . 6 6 , N O . 1 5 , S U P P L B , 2 0 1 5 B301Existing therapies have multiple shortcomings and ischemic cardio-
myopathy is growing at a rampant rate. We report on the early clinical
use of a novel transcatheter technology which addresses the under-
lying problem of the disease, excessive wall tension causing ongoing
ventricular dilation.
METHODS The Revivent System was developed to place permanent
cardiac implants into the heart for the purpose of excluding scar from
the ventricular cavity, thereby reconﬁguring abnormal cardiac geom-
etry that leads to dysfunction. This is achieved by implanting a series of
micro anchors which pull the LV free wall against the septum. The
procedure does not require sternotomy, ventriculotomy nor cardio-
pulmonary bypass. By excluding the abnormal, non-contractile, scar-
red portion of the ventricular wall, volume and radius are diminished
easing wall tension. The Revivent components consist of a series of
catheters and anchors that are deployed using ﬂuoroscopic imaging.
RESULTS Data is presented on 70 subjects treated with the anchor
implants wherein the delivery method was surgical for the ﬁrst 50 pa-
tients (Cohort 1) and transcatheter on the subsequent 20 patients
(Cohort 2). Patients in both Cohorts are indistinguishable clinically and
statistically from the entire group. Quality of Life, 6minutewalk, NYHA
class, EF and LV volume are all improved in early follow up. Procedural
success of the Revivent System was high, regardless of the delivery
system used. Placement of the implant using surgical delivery system
was successful in all but one of the attempted cases (98.1%) but 100%
successful for the transcatheter delivery system. Operative and 30 day
mortality was 5.5%. Mean time to extubation was shorter for patients
treated with the transcatheter system (20 hours) compared to the sur-
gical system (34.6 hours), and had a shorter interval in the ICU (80 hours
vs. 109 hours). Data are presented in Tables 1-4.
CONCLUSIONS These early clinical results suggest that the Revivent
system for less invasive ventricular volume reduction and reshaping
is safe and feasible when applied to appropriate subjects suffering
from ischemic cardiomyopathy heart failure. The clinical and hemo-
dynamic improvement experienced by these patients treated with this
early iteration of the system was demonstrated in measurable post
operative differences in NYHA, QOL, EF, 6 minute walk, and LV vol-
ume. We advocate further clinical investigations of this promising
new technology which ﬁlls an important clinical need.
CATEGORIES STRUCTURAL: Heart FailureCONGENITAL AND OTHER
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BACKGROUND Cardiac or pulmonary right-to-left shunt (RLS) is
associated with aura with or without migraine headache. A quantita-
tive relation between visual aura and degree of RLS is not completely
established. The aim of this study was to assess the relationship be-
tween the degree of RLS and visual aura with migraine.
METHODS Patients referred to the UCLA Interventional Cardiology
program and received a transcranial Doppler (TCD) examination for
assessment of patent foramen ovale (PFO) related conditions prior to
any intervention were enrolled in this study. The study population was
divided into two groups according to the frequency of visual aura with
their migraine headache: migraine headache with frequent (50%) vi-
sual aura (frequent aura group); andmigraine headachewith occasional
(<50%) or novisual aura (occasional or no aura group). Patientswhohad
visual aurawithoutmigraine headachewere classiﬁed into the frequent
aura group. The degree of RLS was quantiﬁed by TCD using the Spencer
grade scale at rest and post-Valsalva. Patients who hadmigraine events
more than one time per month and who also received PFO closure were
assessed for improvement of migraine headache or visual aura symp-
toms at 3 months after PFO closure.RESULTS Of 141 subjects with migraine, 81 (57%) were classiﬁed into
the frequent aura group and 60 (43%) were classiﬁed into the occa-
sional or no aura group. TCD grade in the frequent aura group was
signiﬁcantly greater than those in the occasional or no aura group
both at rest and post-Valsalva (Table). Of 54 patients who received
PFO closure, those in the frequent aura group had a signiﬁcantly
higher frequency of migraine improvement than those in the
occasional or no aura group (p ¼ 0.02).Frequent
aura groupOccasional or no aura
groupp value(n [ 81) (n [ 60)Age, yrs 48  15 50  13 0.55
TCD grade at rest, n ¼
140*3.2  1.5 2.1  1.6 < 0.01TCD grade post-
Valsalva, n ¼ 126*
4.3  1.0 3.8  1.3 0.01Increase in TCD grade,
n ¼ 125*
1.3  1.2 2.0  1.3 < 0.01PFO closed, n** 32 22 -Migraine improved, n
(%)23 (72%) 9 (41%) 0.02Migraine resolved, n
(%)10 (31%) 5 (23%) 0.55PFO: patent foramen ovale; TCD: transcranial Doppler.
*There were 15 patients who had TCD only at rest and 1 patient who had TCD only post-Valsalva. **The
number of patients who had migraine more than 1 time per month and also received PFO closure.
CONCLUSIONS Migraineurs who have frequent visual aura with or
without headache have a greater degree of RLS than migraineurs with
infrequent visual aura. Migraine with frequent visual aura (>50%)
may have a greater potential to improve after PFO closure compared
to migraine with infrequent visual aura.
CATEGORIES STRUCTURAL: Congenital and Other Structural Heart
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BACKGROUND One to ﬁve percent of AF ablations may be compli-
cated by pulmonary vein stenosis (PVS). Initial management of high
grade stenosis is performed with balloon angioplasty or stents.
Restenosis occurs frequently. We sought to assess our center’s out-
comes in patients with restenosis following an initially successful
intervention.
METHODS One hundred and ﬁfty seven patients with PVS were
seen between Jan. 2000 and Nov. 2014. One hundred and twelve
patients had high grade stenosis (75% narrowing on CT imaging)
and were taken for intervention. Restenosis was deﬁned as recur-
rent high grade stenosis more than 1 month following the ﬁrst
procedure.
RESULTS One hundred and twelve patients were taken for initial
intervention in 216 veins. Eighty eight veins were treated with an-
gioplasty (41%), 81 with stenting (37%), and 47 veins (22%) received no
intervention due to complete occlusion or angiographically insigniﬁ-
cant obstruction. Stents signiﬁcantly reduced recurrence relative to
angioplasty (RRR 0.54, p¼0.008). Despite a 94% acute success rate, 43
patients (38%) had 64 vessels which developed high grade restenosis
over a median follow up of 4.6 years. Average time to restenosis was 7
months (range 1-36 months). Forty veins (62.5%) had been treated
with angioplasty. Twenty four veins (37.5%) had been treated with a
stent- 21 were peripheral bare metal stents (median diameter 10 mm)
and 3 were drug eluting stents (median diameter 4 mm). Stents were
sized to the largest achievable diameter. Forty two patients under-
went a second intervention (n¼59 vessels), however 2 of these veins
were occluded and a wire could not be passed. One patient was
asymptomatic and was monitored with CTs for progression. Stenting
was used frequently to treat restenosis, with 33 veins undergoing
stenting (58%) and 23 veins treated with balloon angioplasty (40%).
Vessels treated with initial angioplasty followed by stenting had a
